shutterstock_1201562074_designer491

designer491 / Shutterstock.com

24 December 2019Big PharmaSarah Morgan

Sandoz and Momenta to pay $120m to end antitrust suit

Sandoz and Momenta have agreed to pay $120 million to bring an antitrust class action over blockbuster blood clot drug enoxaparin to an end.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Momenta to pay $35m to end enoxaparin class-action suit

12 December 2019 Momenta Pharmaceuticals has agreed to pay $35 million to settle a 2015 class-action suit that claimed that it blocked generics of the blockbuster blood clot drug enoxaparin from coming to market.

Judge approves $120m Momenta and Sandoz settlement

6 January 2020 A US federal judge has given preliminary approval to the proposed settlement in the class action suit led by Nashville General Hospital against Momenta Pharmaceuticals and Sandoz over their alleged manipulation of drug testing protocols.

More on this story

Momenta to pay $35m to end enoxaparin class-action suit

12 December 2019 Momenta Pharmaceuticals has agreed to pay $35 million to settle a 2015 class-action suit that claimed that it blocked generics of the blockbuster blood clot drug enoxaparin from coming to market.

Judge approves $120m Momenta and Sandoz settlement

6 January 2020 A US federal judge has given preliminary approval to the proposed settlement in the class action suit led by Nashville General Hospital against Momenta Pharmaceuticals and Sandoz over their alleged manipulation of drug testing protocols.

More on this story

Momenta to pay $35m to end enoxaparin class-action suit

12 December 2019 Momenta Pharmaceuticals has agreed to pay $35 million to settle a 2015 class-action suit that claimed that it blocked generics of the blockbuster blood clot drug enoxaparin from coming to market.

Judge approves $120m Momenta and Sandoz settlement

6 January 2020 A US federal judge has given preliminary approval to the proposed settlement in the class action suit led by Nashville General Hospital against Momenta Pharmaceuticals and Sandoz over their alleged manipulation of drug testing protocols.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent